Management of mitral regurgitation in short simple steps

Reading File

Searching for mitral regurgitation management guidelines now.

search_medical_text

mitral regurgitation management treatment guidelines

Advanced Training Statement on Interventional Cardiology

Page 25

search_medical_text

mitral valve surgery indications repair replacement

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 7367

GradeResponse

Mitral Regurgitation (MR) Management

Step 1 — Classify the MR

Type	Cause	Key Feature
Primary (Organic)	Valve leaflet/chordae disease (MVP, rheumatic, endocarditis)	Valve itself is abnormal
Secondary (Functional)	LV dilation/dysfunction pulls leaflets apart	Valve is structurally normal

Step 2 — Assess Severity & Symptoms

Echocardiography is the cornerstone — assess jet severity, LV size/function (EF, LV end-systolic diameter [LVESD])
Severe MR defined as: effective regurgitant orifice area (EROA) ≥ 0.4 cm² (primary) or ≥ 0.2 cm² (secondary)

Step 3 — Medical Management

Primary MR:

No proven therapy delays surgery in asymptomatic severe MR
Treat comorbidities (hypertension, AF, heart failure)

Secondary MR:

Goal-directed medical therapy (GDMT) first: ACE inhibitors/ARBs, beta-blockers, MRAs, SGLT2 inhibitors
CRT (cardiac resynchronization therapy) if LBBB present — can reduce functional MR significantly

Step 4 — Indications for Intervention

(Harrison's, p. 7367; ACC/AHA Guidelines)

Primary MR — operate when:

Symptomatic severe MR (any EF) — especially if repair feasible ✅
Asymptomatic severe MR + EF ≤ 60% or LVESD ≥ 40 mm
Asymptomatic + progressive LV deterioration on serial echo
High likelihood (>95%) of durable repair + low surgical risk

Secondary MR — intervene when:

Persistent severe MR despite optimal GDMT
TEER criteria met (COAPT trial criteria — see below)

Step 5 — Type of Intervention

Option	When Used
Mitral Valve Repair	Preferred for primary MR; lower mortality, preserves LV function
Mitral Valve Replacement	When repair not feasible
TEER (MitraClip/PASCAL)	Primary MR: high/prohibitive surgical risk; Secondary MR: meets COAPT criteria

COAPT trial criteria for TEER in secondary MR:

Severe secondary MR on optimal GDMT
EF 20–50%, LVESD ≤ 70 mm
No severe pulmonary hypertension or severe RV dysfunction

Step 6 — Follow-Up for Asymptomatic Patients

Severity	Echo Interval
Mild MR	Every 3–5 years
Moderate MR	Every 1–2 years
Severe MR (no surgery)	Every 6–12 months

Quick Summary Algorithm

MR diagnosed
    ↓
Primary or Secondary?
    ↓
Severity assessment (Echo)
    ↓
Severe MR?
  ├── YES → Symptomatic? → YES → Surgery (repair preferred)
  │               ↓ NO
  │         EF ≤60% or LVESD ≥40mm? → YES → Surgery
  │               ↓ NO
  │         Watch & serial echo
  └── NO → Medical Rx + surveillance
    ↓
Secondary MR → GDMT first → Persistent? → Consider TEER (COAPT criteria)

(Advanced Training Statement on Interventional Cardiology, p. 25; Harrison's, p. 7367)

This is a shared conversation. Sign in to Orris to start your own chat.